PT1725536E - Derivados de imidazolina apresentando actividade antagonista cb1 - Google Patents

Derivados de imidazolina apresentando actividade antagonista cb1 Download PDF

Info

Publication number: PT1725536E
Authority: PT; Portugal
Prior art keywords: imidazoline derivatives; antagonistic activity; compounds; preparation; methods
Prior art date: 2004-02-19

Application number

PT05716710T

Other languages

English (en)

Inventor

Cornelis G Kruse

Josephus H M Lange

Herman H Van Stuivenberg

Original Assignee

Solvay Pharm Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-19

Filing date

2005-02-16

Publication date

2009-01-22

2005-02-16 Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv

2009-01-22 Publication of PT1725536E publication Critical patent/PT1725536E/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/16—Radicals substituted by nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms

PT05716710T 2004-02-19 2005-02-16 Derivados de imidazolina apresentando actividade antagonista cb1 PT1725536E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US54548404P	2004-02-19	2004-02-19
EP04100656		2004-02-19

Publications (1)

Publication Number	Publication Date
PT1725536E true PT1725536E (pt)	2009-01-22

Family

ID=34889023

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT05716710T PT1725536E (pt)	2004-02-19	2005-02-16	Derivados de imidazolina apresentando actividade antagonista cb1

Country Status (17)

Country	Link
EP (1)	EP1725536B8 (pt)
JP (1)	JP2007523128A (pt)
KR (1)	KR20060131908A (pt)
AT (1)	ATE411296T1 (pt)
AU (1)	AU2005214084B2 (pt)
CA (1)	CA2553372A1 (pt)
DE (1)	DE602005010401D1 (pt)
DK (1)	DK1725536T3 (pt)
ES (1)	ES2315851T3 (pt)
HR (1)	HRP20080689T3 (pt)
IL (1)	IL176546A (pt)
NO (1)	NO20064238L (pt)
PL (1)	PL1725536T3 (pt)
PT (1)	PT1725536E (pt)
RU (1)	RU2357958C2 (pt)
SI (1)	SI1725536T1 (pt)
WO (1)	WO2005080345A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
TW200825067A (en) *	2006-10-23	2008-06-16	Lilly Co Eli	CB1 compounds
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN102007121B (zh)	2008-04-22	2013-08-14	伊莱利利公司	作为cb-1配体的1，5-二苯基-吡咯烷-2-酮化合物
CN102119029B (zh) *	2008-04-22	2013-03-13	伊莱利利公司	作为cb-1配体的1，5-二苯基-吡咯烷-2-酮化合物
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2771278A1 (en)	2009-08-26	2011-03-03	Sanofi	Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de)	2011-03-08	2015-06-24	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA78523C2 (en) *	2001-09-21	2007-04-10	Solvay Pharm Bv	4,5-dihydro-1h-pyrazoie derivatives as cb1 antagonists
TWI231757B (en) *	2001-09-21	2005-05-01	Solvay Pharm Bv	1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
AR038966A1 (es) *	2002-03-18	2005-02-02	Solvay Pharm Bv	Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
US6878735B2 (en) *	2002-05-31	2005-04-12	Board Of Trustees Of Michigan State University	Multi-substituted imidazolines and method of use thereof

2005
- 2005-02-16 ES ES05716710T patent/ES2315851T3/es active Active
- 2005-02-16 DE DE602005010401T patent/DE602005010401D1/de active Active
- 2005-02-16 RU RU2006133373/04A patent/RU2357958C2/ru not_active IP Right Cessation
- 2005-02-16 EP EP05716710A patent/EP1725536B8/en active Active
- 2005-02-16 PL PL05716710T patent/PL1725536T3/pl unknown
- 2005-02-16 SI SI200530522T patent/SI1725536T1/sl unknown
- 2005-02-16 DK DK05716710T patent/DK1725536T3/da active
- 2005-02-16 WO PCT/EP2005/050680 patent/WO2005080345A2/en active Application Filing
- 2005-02-16 JP JP2006553588A patent/JP2007523128A/ja not_active Ceased
- 2005-02-16 PT PT05716710T patent/PT1725536E/pt unknown
- 2005-02-16 AT AT05716710T patent/ATE411296T1/de active
- 2005-02-16 AU AU2005214084A patent/AU2005214084B2/en not_active Ceased
- 2005-02-16 KR KR1020067019318A patent/KR20060131908A/ko not_active Application Discontinuation
- 2005-02-16 CA CA002553372A patent/CA2553372A1/en not_active Abandoned
2006
- 2006-06-26 IL IL176546A patent/IL176546A/en not_active IP Right Cessation
- 2006-09-19 NO NO20064238A patent/NO20064238L/no not_active Application Discontinuation
2008
- 2008-12-31 HR HR20080689T patent/HRP20080689T3/xx unknown

Also Published As

Publication number	Publication date
WO2005080345A2 (en)	2005-09-01
DE602005010401D1 (de)	2008-11-27
WO2005080345A3 (en)	2006-12-21
EP1725536B1 (en)	2008-10-15
SI1725536T1 (sl)	2009-04-30
DK1725536T3 (da)	2009-02-16
KR20060131908A (ko)	2006-12-20
IL176546A0 (en)	2006-10-31
AU2005214084A1 (en)	2005-09-01
ES2315851T3 (es)	2009-04-01
AU2005214084B2 (en)	2010-06-03
CA2553372A1 (en)	2005-09-01
ATE411296T1 (de)	2008-10-15
RU2006133373A (ru)	2008-03-27
EP1725536A2 (en)	2006-11-29
IL176546A (en)	2010-06-30
RU2357958C2 (ru)	2009-06-10
JP2007523128A (ja)	2007-08-16
PL1725536T3 (pl)	2009-04-30
HRP20080689T3 (en)	2009-05-31
EP1725536B8 (en)	2009-04-22
NO20064238L (no)	2006-11-20

Publication	Publication Date	Title
EP1725536B8 (en)	2009-04-22	Imidazoline derivatives having cb1-antagonistic activity
MY140693A (en)	2010-01-15	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200517388A (en)	2005-06-01	Thiazole derivatives as cannabinoid receptor modulators
MY148480A (en)	2013-04-30	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TW200635903A (en)	2006-10-16	Therapeutic agents
IL187438A0 (en)	2008-02-09	Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
MY138478A (en)	2009-06-30	Benzazepine derivatives for the treatment of neurological disorders
UA92503C2 (ru)	2010-11-10	Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
TW200531689A (en)	2005-10-01	Therapeutic agents
TW200504034A (en)	2005-02-01	Therapeutic agents
TW200503710A (en)	2005-02-01	Novel compounds
WO2004009549A3 (en)	2004-06-03	Piperidines useful for the treatment of central nervous system disorders
TW200633986A (en)	2006-10-01	Therapeutic agents
HK1069169A1 (en)	2005-05-13	Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
EP1817312A4 (en)	2009-11-04	MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
GB0513886D0 (en)	2005-08-10	Novel compounds
TW200505865A (en)	2005-02-16	Compounds useful for the treatment of diseases
TW200514781A (en)	2005-05-01	Novel compounds
UA84896C2 (ru)	2008-12-10	Производные гидронопола как агонисты человеческих рецепторов orl1
TW200509933A (en)	2005-03-16	Therapeutic agents
EP1736470A3 (en)	2007-04-04	Pyrimidine derivatives as CB2 cannabinoid receptor modulators
TW200519101A (en)	2005-06-16	Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
MXPA05004273A (es)	2005-10-18	Derivados de fenilalquil y piridilalquil piperazina.
IL173436A0 (en)	2006-06-11	1h-imidazole derivatives as cannabinoid receptor modulators
MXPA05011163A (es)	2005-12-14	Derivados de 3-benzhidriliden-8-azabiciclo[3.2.1]octano con actividad de receptores opioides.